By-health(SZ:300146) Xin Lang Cai Jing·2025-11-18 01:34Core Insights - The stock of Tongrentang fell by 0.94% on November 17, with a trading volume of 353 million yuan [1] - As of November 17, the net financing purchase was 15.64 million yuan, with a total financing and securities balance of 815 million yuan [1] Financing Summary - On November 17, Tongrentang had a financing purchase of 53.32 million yuan, with a current financing balance of 804 million yuan, accounting for 3.77% of the circulating market value [1] - The financing balance is below the 50th percentile level over the past year, indicating a low position [1] Securities Lending Summary - On November 17, Tongrentang repaid 3,100 shares and sold 7,900 shares, with a selling amount of 99,500 yuan [1] - The securities lending balance was 10.49 million yuan, exceeding the 90th percentile level over the past year, indicating a high position [1] Company Overview - Tongrentang was established on April 1, 2005, and listed on December 15, 2010, primarily engaged in the research, production, and sales of dietary supplements [1] - The revenue composition includes: Other 38.02%, Capsules 27.84%, Tablets 20.38%, Powders 13.76% [1] Financial Performance - As of September 30, 2025, Tongrentang reported a revenue of 4.915 billion yuan, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders was 907 million yuan, a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the A-share listing amount to 8.321 billion yuan, with 2.429 billion yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, the number of shareholders was 71,100, a decrease of 0.14% from the previous period [2] - The second-largest circulating shareholder is E Fund's ChiNext ETF, holding 20.85 million shares, a decrease of 3.746 million shares from the previous period [2]